Gilead weakness creates buying opportunity, says RBC Capital

After Gilead's (GILD) stock fell following Merck's (MRK) acquisition of Idenix (IDIX), RBC Capital expects Sovaldi sales to come in well above consensus estimates for 2015, potentially enabling Gilead's EPS to reach $8-$10. RBC Capital says that the market expects the sales of HCV treatments to drop significantly in 2016, but the firm does not agree with this outlook. RBC Capital keeps an Outperform rating on Gilead.